Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized …
PA Philip, B Goldman, RK Ramanathan, HJ Lenz… - Cancer, 2014 - Wiley Online Library
BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely
to affect its natural history. We tested the hypothesis that simulataneous targeting of the …
to affect its natural history. We tested the hypothesis that simulataneous targeting of the …
Targeting epidermal growth factor receptor–related signaling pathways in pancreatic cancer
PA Philip, MP Lutz - Pancreas, 2015 - journals.lww.com
Pancreatic cancer is aggressive, chemoresistant, and characterized by complex and poorly
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …
understood molecular biology. The epidermal growth factor receptor (EGFR) pathway is …
Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic …
HL Kindler, T Gangadhar, T Karrison… - Journal of Clinical …, 2008 - ascopubs.org
4502 Background: Targeting several critical pathways may be more effective than single
pathway blockade in a resistant cancer like PC. In preclinical PC models, combining EGFR+ …
pathway blockade in a resistant cancer like PC. In preclinical PC models, combining EGFR+ …
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
T Semrad, A Barzi, HJ Lenz, IM Hutchins… - International journal of …, 2015 - Springer
Purpose Erlotinib marginally improves survival when administered continuously with
gemcitabine to patients with advanced pancreatic cancer; however, preclinical data suggest …
gemcitabine to patients with advanced pancreatic cancer; however, preclinical data suggest …
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
AH Ko, AP Venook, EK Bergsland, RK Kelley… - Cancer chemotherapy …, 2010 - Springer
Purpose No standard of care exists for patients with metastatic pancreatic cancer following
progression on first-line chemotherapy. Based on potential for additive or synergistic activity …
progression on first-line chemotherapy. Based on potential for additive or synergistic activity …
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways
H Burris III, C Rocha-Lima - The oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the existing chemotherapeutic options for advanced pancreatic cancer. Interpret …
Evaluate the existing chemotherapeutic options for advanced pancreatic cancer. Interpret …
A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and …
W Vervenne, J Bennouna, Y Humblet, S Gill… - Journal of Clinical …, 2008 - ascopubs.org
4507 Background: The phase II B+ G trial showed a 21% response rate (RR) with a median
overall survival (OS) of 8.8 months [Kindler, JCO 2005]. In the phase III OS trial of G+ E vs. G …
overall survival (OS) of 8.8 months [Kindler, JCO 2005]. In the phase III OS trial of G+ E vs. G …
Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG …
PA Philip, J Benedetti, C Fenoglio-Preiser… - Journal of Clinical …, 2007 - ascopubs.org
LBA4509 Background: Epidermal growth factor receptor [EGFR] pathway is a rational target
for therapeutic intervention. This study tested the efficacy of an anti-EGFR monoclonal …
for therapeutic intervention. This study tested the efficacy of an anti-EGFR monoclonal …
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
E Van Cutsem, WL Vervenne, J Bennouna… - Journal of clinical …, 2009 - ascopubs.org
Purpose Treatment with gemcitabine provides modest benefits in patients with metastatic
pancreatic cancer. The addition of erlotinib to gemcitabine shows a small but significant …
pancreatic cancer. The addition of erlotinib to gemcitabine shows a small but significant …
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma …
E Assenat, L Mineur, C Mollevi… - … journal of cancer, 2021 - Wiley Online Library
In a previous phase II study (THERAPY), cetuximab and trastuzumab combination, as
second‐line after progression with gemcitabine, showed disease stabilization in 27% of 33 …
second‐line after progression with gemcitabine, showed disease stabilization in 27% of 33 …